Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder

Ralf W. Dittmann; Esther Cardo; Peter Nagy; Colleen S. Anderson; Ben Adeyi; Beatriz Caballero; Paul Hodgkins; Richard Civil; David R. Coghill

doi:10.1007/s40263-014-0188-9

Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder

Ralf W. Dittmann (Lead / Corresponding author), Esther Cardo, Peter Nagy, Colleen S. Anderson, Ben Adeyi, Beatriz Caballero, Paul Hodgkins, Richard Civil, David R. Coghill

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

218 Downloads (Pure)

Abstract

A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.

Original language	English
Pages (from-to)	1059-1069
Number of pages	11
Journal	CNS Drugs
Volume	28
Issue number	11
DOIs	https://doi.org/10.1007/s40263-014-0188-9
Publication status	Published - Nov 2014

Access to Document

10.1007/s40263-014-0188-9

Publisher final version
©The Author(s) 2014. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which per- mits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
Final published version, 586 KBLicence: CC BY-NC

http://link.springer.com/journal/40263

Cite this

Dittmann, R. W., Cardo, E., Nagy, P., Anderson, C. S., Adeyi, B., Caballero, B., Hodgkins, P., Civil, R., & Coghill, D. R. (2014). Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. CNS Drugs, 28(11), 1059-1069. https://doi.org/10.1007/s40263-014-0188-9

@article{7b36c536e57f4d64a96691c44d27f78f,

title = "Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder",

abstract = "A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.",

author = "Dittmann, {Ralf W.} and Esther Cardo and Peter Nagy and Anderson, {Colleen S.} and Ben Adeyi and Beatriz Caballero and Paul Hodgkins and Richard Civil and Coghill, {David R.}",

year = "2014",

month = nov,

doi = "10.1007/s40263-014-0188-9",

language = "English",

volume = "28",

pages = "1059--1069",

journal = "CNS Drugs",

issn = "1172-7047",

publisher = "Springer Verlag",

number = "11",

}

Dittmann, RW, Cardo, E, Nagy, P, Anderson, CS, Adeyi, B, Caballero, B, Hodgkins, P, Civil, R & Coghill, DR 2014, 'Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder', CNS Drugs, vol. 28, no. 11, pp. 1059-1069. https://doi.org/10.1007/s40263-014-0188-9

Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder. / Dittmann, Ralf W. (Lead / Corresponding author); Cardo, Esther; Nagy, Peter et al.
In: CNS Drugs, Vol. 28, No. 11, 11.2014, p. 1059-1069.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder

AU - Dittmann, Ralf W.

AU - Cardo, Esther

AU - Nagy, Peter

AU - Anderson, Colleen S.

AU - Adeyi, Ben

AU - Caballero, Beatriz

AU - Hodgkins, Paul

AU - Civil, Richard

AU - Coghill, David R.

PY - 2014/11

Y1 - 2014/11

N2 - A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.

AB - A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously.

U2 - 10.1007/s40263-014-0188-9

DO - 10.1007/s40263-014-0188-9

M3 - Article

C2 - 25038977

SN - 1172-7047

VL - 28

SP - 1059

EP - 1069

JO - CNS Drugs

JF - CNS Drugs

IS - 11

ER -

Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder

Abstract

Access to Document

Fingerprint

Cite this